MarketBeat
15 Jul 2026, 08:02 UTC · 9w ago
Verdict
Headline leans bullish. We score CELC +1.00 across five claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+1.00strongly bullish
What the story claims
5 claims · scored −1 bearish … +1 bullish
The FDA granted full approval for REVTORPYK for the treatment of certain HR-positive, HER2-negative advanced breast cancers without a PIK3CA mutation.
More positive than 99% of claims this week
Celcuity estimates a served market opportunity of over $6 billion for the second-line setting, potentially exceeding $10 billion including first-line use.
So whatProvides a quantifiable revenue ceiling and justifies the valuation based on the total addressable market (TAM).
Continue reading
5 related stories
More positive than 98% of ticker scores this week
Scored by the NIS engine · methodology.
Search tags
More positive than 92% of claims this week
Celcuity plans to submit a supplemental NDA in Q3 for patients with PIK3CA mutations to potentially cover the full second-line market.
So whatExpanding the label to mutant populations would increase the addressable patient base from 60% to 100% of the second-line market.
More positive than 86% of claims this week
In Phase III trials, the triplet regimen showed a 7.3-month improvement in progression-free survival over fulvestrant monotherapy (9.3 months vs 2 months).
More positive than 77% of claims this week
The company expects commercial launch later in Q3, contingent on ensuring sufficient drug supply.
More positive than 50% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
The company received FDA approval for REVTORPYK, marking a transformative transition to a commercial-stage business with a significant market opportunity.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
2h ago
−24.4%
Price is moving against the score
$84.00 vs $111.05 close before publication (Jul 14) · not market-adjusted
CELC chart →
